| Literature DB >> 35656624 |
Sang Yoon Kim1, Jae Myung Park2,3.
Abstract
Esophagogastroduodenoscopy (EGD) has been used to diagnose a wide variety of upper gastrointestinal diseases. In particular, EGD is used to screen high-risk subjects of gastric cancer. Quality control of EGD is important because the diagnostic rate is examiner-dependent. However, there is still no representative quality indicator that can be uniformly applied in EGD. There has been growing awareness of the importance of quality control in improving EGD performance. Therefore, we aimed to review the available and emerging quality indicators for diagnostic EGD.Entities:
Keywords: Detection rate; Esophagogastroduodenoscopy; Guideline; Neoplasms; Quality indicators
Year: 2022 PMID: 35656624 PMCID: PMC9178133 DOI: 10.5946/ce.2022.094
Source DB: PubMed Journal: Clin Endosc ISSN: 2234-2400
Fig. 1.Photodocumentation in a normal endoscopic examination.
Endoscopic classification systems
| Abnormal finding | Classification | Grade |
|---|---|---|
| Erosive esophagitis | Los Angeles | A, B, C, D |
| Barrett’s esophagus | Prague | Circumferential extent, maximal extent |
| Eosinophilic esophagitis | Endoscopic reference score | EREFS (edema, rings, exudate, furrows, stricture) |
| Caustic esophagitis | Zagar | I, IIa, IIb, IIIa, IIIb, IV |
| Esophageal varices | Baveno | Small (I), medium (II), large (III) |
| Hiatal hernia | Hill | I, II, III, IV |
| Ulcer bleeding | Forrest | Ia, Ib, IIa, IIb, IIc, III |
| Duodenal adenomas in patients with FAP | Spigelman | 0, I, II, III, IV |
| Neoplasia | Paris | 0-Ip, 0-Is, 0-IIa, 0-IIb, 0-IIc, 0-III |
FAP, familial adenomatous polyposis.
Summary of studies for association with observation time and neoplasm detection rate in esophagogastroduodenoscopy
| Study | Country | Design of study | No. of subjects | No. of endoscopists | Primary outcome | Observation time (cutoff time) | Result |
|---|---|---|---|---|---|---|---|
| Gupta et al. | USA | Prospective study, multicenter | 112 Subjects with Barret’s esophagus, surveillance | 11 | HGD and EAC | Barrett’s inspection time (>1 min/cm [slow] vs. ≤1 min/cm [fast] in esophagus) | Detection rate of HGD and EAC (fast group, 6.7% vs. slow group, 40.2%; |
| Teh et al. | Singapore | Retrospective study, single center | 837 Subjects, symptomatic | 16 (8 staffs and 8 trainees) | High-risk gastric lesions (atrophic gastritis, intestinal metaplasia, dysplasia, cancer) | Total EGD examination time (>7 min [slow] vs. ≤7 min [fast]) | Detection rate of high-risk gastric lesions (fast group, 6.1% vs. slow group, 14.0%; |
| Factors associated with detection of high-risk gastric lesions (slow endoscopists OR, 2.50; 95% CI, 1.52–4.12) | |||||||
| Kawamura et al. | Japan | Retrospective study, single center | 55,786 Subjects (including asymptomatic 15,763 subjects) | 20 | Upper GI neoplasia | Total EGD examination time (>7 min [slow] and 5–7 min [moderate] vs. <5 min [fast]) | Detection rate of upper GI neoplasia (fast group, 0.57%; moderate group, 0.97%; and slow group, 0.94%) |
| Factors associated with detection of upper GI neoplasia (5–7 min: OR, 1.90; 95% CI, 1.06–3.40; | |||||||
| (>7 min: OR, 1.89; 95% CI, 0.98–3.64; | |||||||
| Park et al. | Korea | Retrospective study, single center | 111,962 Subjects, asymptomatic | 14 | Upper GI neoplasia | Withdrawal time from duodenum (>3 min [slow] vs. ≤3 min [fast]) | Detection rate of upper GI neoplasia (fast group, 0.20% vs. slow group, 0.28%; |
| Factors associated with detection of upper GI neoplasia (slow endoscopists OR, 1.52; 95% CI, 1.17–1.97; | |||||||
| Park et al. | Korea | Prospective observational study, single center | 30,506 Subjects, asymptomatic | 14 | Upper GI neoplasia with prolonged observation time (intervention endoscopists vs. baseline endoscopists) | Withdrawal time from duodenum (prolonged observation time >3 min [intervention] vs. >3 min [baseline]) | Detection rate of upper GI neoplasia (baseline, 0.234% vs. intervention group, 0.331%; |
| Factors associated with detection of upper GI neoplasia (prolonged observation time of >3 min [intervention]: OR, 1.51; 95% CI, 1.21–1.75; |
EGD, esophagogastroduodenoscopy; HGD, high-grade dysplasia; EAC, esophageal adenocarcinoma; OR, odds ratio; CI, confidence interval; GI, gastrointestinal.
Fig. 2.Classification of quality indicators into premedication, photodocumentation, reporting, observation time, biopsy rate/protocol, endoscopy education, image enhanced endoscopy, and artificial intelligence.
Summary of quality indicators recommended in several guidelines
| Quality indicator | Asian consensus (2019) | KSGE (2018) | ESGE (2016) | ASGE (2015) | BSG (2017) |
|---|---|---|---|---|---|
| Use of mucolytic/defoaming agent | Use of mucolytic and/or defoaming agents is recommended for visual clarity of EGD. | Not specified | Not specified | Not specified | Adequate mucosal visualization should be achieved by a combination of adequate air insufflation, and mucosal cleansing |
| Use of antispasmodic agent | Use of an antispasmodic agent is recommended to enhance the detection rate of EGD. | Not specified | Not specified | Not specified | Not specified |
| Use of sedation | Use of sedation is recommended to enhance the detection rate of EGD. | When required: need for monitoring patient’s vital sign | When required: need for patient’s monitoring and assessment of adverse event | Not specified | When required: intravenous sedation and local anesthetic throat spray can be used |
| Photodocumentation | Systematic endoscopic mapping (22 images) may improve the detection rate of upper GI neoplasm | Photodocumentation after careful inspection that include at least 8 clear standard EGD images plus any pathologic lesions. | Photodocumentation includes at least 10 representative pictures of anatomical landmarks plus any abnormal findings | Photodocumentation of the esophagus, stomach, and duodenum is conducted plus any abnormalities | Minimum 8 anatomical landmarks+any detected lesion |
| Presence of an inlet patch or hiatus hernia should be photodocumented | |||||
| Reporting | Not specified | Baseline information, diagnosis, findings, biopsy details, and complication are required in report | Abnormal findings should be reported according to available standardized terminology | Complete procedure report is required | A report summarizes the endoscopy findings and recommendations |
| Observation time | Sufficient examination time is recommended to increase the detection rate of upper GI neoplasia | Not specified | Minimum 7 min procedure time from intubation to extubation in the first and follow-up EGDs for gastric intestinal metaplasia | Not specified | Minimum 7 min inspection time |
| Biopsy rate/protocol | Not specified | Not specified | Applications of the MAPS (4 biopsy protocol): at least 2 biopsies from the antrum and the body, respectively | Four or more biopsies in non-bleeding ulcers to exclude malignancy | Minimum of 6 biopsies: malignant-looking lesion |
| Use of Seattle biopsy protocol for Barrett’s esophagus | Use of Seattle biopsy protocol for Barrett’s esophagus | Biopsies from the antrum and body: endoscopic features of gastric atrophy or intestinal metaplasia | |||
| Representative biopsies: gastric polyps | |||||
| Seattle biopsy protocol: no lesions within Barrett’s segment | |||||
| Targeted biopsies: a lesion within Barrett’s segment | |||||
| Endoscopy education | Structured training improves the detection rate of upper GI neoplasia | Endoscopists are required to receive continuous endoscopy education | Not specified | Not specified | Not specified |
| Image enhanced endoscopy | IEE improves the detection rate of esophageal superficial neoplasia and gastric premalignant mucosal changes | Not specified | Use of Lugol’s chromoendoscopy for suspected squamous neoplasia | Not specified | Esophageal squamous neoplasia is suspected, full assessment with enhanced imaging and/or Lugol’s chromoendoscopy |
| Artificial intelligence | Not specified | Not specified | Not specified | Not specified | Not specified |
KSGE, Korean Society of Gastrointestinal Endoscopy; ESGE, European Society of Gastrointestinal Endoscopy; ASGE, American Society for Gastrointestinal Endoscopy; BSG, British Society of Gastroenterology; EGD, esophagogastroduodenoscopy; GI, gastrointestinal; MAPS, management of precancerous conditions and lesions in the stomach; IEE, image enhanced endoscopy.